BioSpace News Archive

Oncotelic Therapeutics, Inc announced the launch of Pet2DAO Inc., a wholly owned subsidiary of Oncotelic, and its associated token PDAO.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) announced today that the Company has entered into a binding agreement (the “Arrangement Agreement”) with Shockwave Medical, Inc. (“Shockwave”), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the “Common Shares”) of the Company (the “Transaction”).

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina.

SOFIE Biosciences, an established US manufacturer and developer of radiopharmaceuticals, will be supporting, through companion diagnostic [68Ga]FAPI-46 PET, Yantai LNC Biotechnology’s recently FDA accepted clinical study.

MedRhythms announced today that the company’s pivotal trial for MR-001, a novel digital intervention in development to treat gait deficits in chronic stroke, was successfully completed and met its primary endpoint.

BioCentriq, Inc. announced today that they have successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial.

Curate Biosciences today announced the commercial launch of its Curate® Cell Processing System.

Be The Match BioTherapies® announced it is offering CIBMTR® Clinical Research Organization Services, which allows sponsors to significantly reduce the time required to launch and execute high-impact clinical trials.

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023.

Indapta Therapeutics, Inc. today announced it has appointed Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations.